Inogen (INGN) Set to Announce Quarterly Earnings on Thursday

Inogen (NASDAQ:INGN) will release its earnings data after the market closes on Thursday, November 7th. Analysts expect Inogen to post earnings of ($0.51) per share for the quarter. Inogen has set its FY 2024 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical technology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.31. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The company had revenue of $88.77 million during the quarter, compared to analyst estimates of $82.50 million. During the same period in the previous year, the company earned ($0.42) earnings per share. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, analysts expect Inogen to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Inogen Stock Down 1.0 %

Shares of INGN stock opened at $9.27 on Thursday. Inogen has a 12 month low of $4.37 and a 12 month high of $13.33. The firm has a market cap of $218.56 million, a PE ratio of -2.23 and a beta of 1.04. The stock has a 50 day moving average of $10.47 and a 200-day moving average of $9.29.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. StockNews.com upgraded Inogen from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Inogen presently has an average rating of “Hold” and a consensus target price of $7.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.